These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 20356929)

  • 1. Breaking down the barriers: siRNA delivery and endosome escape.
    Dominska M; Dykxhoorn DM
    J Cell Sci; 2010 Apr; 123(Pt 8):1183-9. PubMed ID: 20356929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in synthetic siRNA delivery.
    Manjunath N; Dykxhoorn DM
    Discov Med; 2010 May; 9(48):418-30. PubMed ID: 20515610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
    Aigner A
    J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape.
    Endoh T; Ohtsuki T
    Adv Drug Deliv Rev; 2009 Jul; 61(9):704-9. PubMed ID: 19383521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged gene silencing in hepatoma cells and primary hepatocytes after small interfering RNA delivery with biodegradable poly(beta-amino esters).
    Vandenbroucke RE; De Geest BG; Bonné S; Vinken M; Van Haecke T; Heimberg H; Wagner E; Rogiers V; De Smedt SC; Demeester J; Sanders NN
    J Gene Med; 2008 Jul; 10(7):783-94. PubMed ID: 18470950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes.
    Oliveira S; van Rooy I; Kranenburg O; Storm G; Schiffelers RM
    Int J Pharm; 2007 Mar; 331(2):211-4. PubMed ID: 17187949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective siRNA delivery and target mRNA degradation using an amphipathic peptide to facilitate pH-dependent endosomal escape.
    Bartz R; Fan H; Zhang J; Innocent N; Cherrin C; Beck SC; Pei Y; Momose A; Jadhav V; Tellers DM; Meng F; Crocker LS; Sepp-Lorenzino L; Barnett SF
    Biochem J; 2011 Apr; 435(2):475-87. PubMed ID: 21265735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of an HIV gp41-derived peptide for enhanced intracellular trafficking of synthetic gene and siRNA delivery vehicles.
    Kwon EJ; Bergen JM; Pun SH
    Bioconjug Chem; 2008 Apr; 19(4):920-7. PubMed ID: 18376855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonviral in vivo delivery of therapeutic small interfering RNAs.
    Aigner A
    Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Barriers to successful delivery of short interfering RNA after systemic administration.
    White PJ
    Clin Exp Pharmacol Physiol; 2008 Nov; 35(11):1371-6. PubMed ID: 18565190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA.
    Liu B
    Brief Funct Genomic Proteomic; 2007 Jun; 6(2):112-9. PubMed ID: 17670766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA interference (RNAi) in hematology.
    Scherr M; Steinmann D; Eder M
    Ann Hematol; 2004 Jan; 83(1):1-8. PubMed ID: 14574462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular siRNA delivery mediated by a cell-permeant RNA-binding protein and photoinduced RNA interference.
    Endoh T; Sisido M; Ohtsuki T
    Bioconjug Chem; 2008 May; 19(5):1017-24. PubMed ID: 18442282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonviral genetic modification mediates effective transgene expression and functional RNA interference in human mesenchymal stem cells.
    Hoelters J; Ciccarella M; Drechsel M; Geissler C; Gülkan H; Böcker W; Schieker M; Jochum M; Neth P
    J Gene Med; 2005 Jun; 7(6):718-28. PubMed ID: 15712343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in cell-type specific delivery of RNAi-based therapeutics.
    Dykxhoorn DM
    IDrugs; 2010 May; 13(5):325-31. PubMed ID: 20432190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A peptide-targeted delivery system with pH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery.
    Wang XL; Xu R; Lu ZR
    J Control Release; 2009 Mar; 134(3):207-13. PubMed ID: 19135104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracellular siRNA and precursor miRNA trafficking using bioresponsive copolypeptides.
    Rahbek UL; Howard KA; Oupicky D; Manickam DS; Dong M; Nielsen AF; Hansen TB; Besenbacher F; Kjems J
    J Gene Med; 2008 Jan; 10(1):81-93. PubMed ID: 18000993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
    DeVincenzo JP
    Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. siRNA-mediated antitumorigenesis for drug target validation and therapeutics.
    Lu PY; Xie FY; Woodle MC
    Curr Opin Mol Ther; 2003 Jun; 5(3):225-34. PubMed ID: 12870431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.